PositiveID reports on market opportunities for homeland security solutions
PositiveID develops microfluidic systems for the automated preparation and performance of biological assays to detect biological threats in high-value and medical environments. William Caragol, the chairman and CEO of PositiveID, said the last decade significantly increased the necessity of biological detection.
"The bio-detection market has seen a surge in funding over the past decade," Caragol said. "This increase can be directly attributed to events that have occurred since the beginning of the 21st century such as the Anthrax scare in 2001, the SARS outbreak in 2003, the ricin letters in 2004, the H1N1 health crisis in 2009, and most recently the concern over Syrian and North Korean biological and chemical weapons programs."
Caragol said PositiveID's technologies may help to protect lives through the faster detection of biological terrorism.
"The urgent requirement for public healthcare and homeland security agencies to institute an early detection system for bio-terrorist attacks and infectious disease outbreaks is at hand," Caragol said. "PositiveID's technologies reduce the time to both detect the presence of a threat and diagnose affected persons, enabling the deployment of countermeasures and vaccines in a time frame where casualties and fatalities can be drastically reduced."
Caragol said the PositiveID's products may revolutionize how the U.S. responds to bioterrorism while also improving medical testing at the point of need.